Antigen-binding proteins targeting CD56 and uses thereof

US10730941B2 · kind B2 · utility

Assignees

• Memorial Sloan Kettering Cancer Center · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Michel Sadelain · New York, US
• Reuben Benjamin · London, GB
• Dimiter S. Dimitrov · Frederick, US
• Yang Feng · Frederick, US

Key dates

• Filing date: Jan 31, 2018
• Grant date: Aug 4, 2020
• Expiry date: Jan 31, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.